scholarly journals The Age Conundrum: A Scoping Review of Younger Age or Adolescent and Young Adult as a Risk Factor for Clinical Distress, Depression, or Anxiety in Cancer

2015 ◽  
Vol 4 (4) ◽  
pp. 157-173 ◽  
Author(s):  
Michael J. Lang ◽  
Victoria David ◽  
Janine Giese-Davis
Keyword(s):  
Risk Factor ◽  
Young Adult ◽  
Scoping Review ◽  
Adolescent And Young Adult ◽  
Younger Age

scholarly journals Adolescent and young adult patients as co‐researchers: A scoping review

2021 ◽  
Author(s):  
Kjersti J. Ø. Fløtten ◽  
Ana Isabel Fernandes Guerreiro ◽  
Ilaria Simonelli ◽  
Anne Lee Solevåg ◽  
Isabelle Aujoulat
Keyword(s):  
Young Adult ◽  
Scoping Review ◽  
Adult Patients ◽  
Adolescent And Young Adult

scholarly journals Modeling Variation in the Reproductive Lifespan of Female Adolescent and Young Adult Cancer Survivors Using AMH

2020 ◽  
Vol 105 (8) ◽  
pp. 2740-2751 ◽  
Author(s):  
H Irene Su ◽  
Brian Kwan ◽  
Brian W Whitcomb ◽  
Ksenya Shliakhsitsava ◽  
Andrew C Dietz ◽  
...  
Keyword(s):  
Young Adult ◽  
Cancer Treatment ◽  
Ovarian Function ◽  
Dried Blood Spots ◽  
Female Adolescent ◽  
Adolescent And Young Adult ◽  
Enzyme Linked Immunosorbent Assay ◽  
Young Adult Cancer Survivors ◽  
Younger Age ◽  
Adult Cancer Survivors

Abstract Context Many female survivors of adolescent and young adult cancers (AYA survivors) have shortened reproductive lifespans. However, the timing and duration of ovarian function after cancer treatment are largely unknown. Objective To model the trajectory of ovarian function over two decades following cancer treatment and evaluate how trajectories vary by treatment gonadotoxicity and age. Design In a prospective cohort, AYA survivors aged 18-39 at variable times since cancer treatment completion provided dried blood spots (DBS) every 6 months for up to 18 months. Anti-Müllerian hormone (AMH) levels were measured using the Ansh DBS AMH enzyme-linked immunosorbent assay. The mean AMH trajectory was modeled for the entire cohort and separately by treatment gonadotoxicity and age using functional principal components analysis. Results 763 participants, mean (standard deviation) enrollment age 33.3 (4.7) and age at cancer diagnosis 25.9 (5.7) years, contributed 1905 DBS samples. The most common cancers were breast (26.9%), lymphoma (24.8%), and thyroid (18.0%). AMH trajectories differed among survivors by treatment gonadotoxicity (low, moderate, or high) (P < 0.001). Following low or moderately gonadotoxic treatments, AMH levels increased over 2-3 years and plateaued over 10-15 years before declining. In contrast, following highly gonadotoxic treatment, AMH levels were lower overall and declined shortly after peak at 2-3 years. Younger age at treatment was associated with higher trajectories, but a protective effect of younger age was not observed in survivors exposed to highly gonadotoxic treatments (Pinteraction < 0.001). Conclusions In this large AYA survivor cohort, timing and duration of ovarian function strongly depended on treatment gonadotoxicity and age at treatment. The findings provide novel, more precise information to guide reproductive decision-making.

A summary of high quality online information resources for parents with cancer who have adolescent and young adult children: A scoping review

2019 ◽  
Vol 28 (12) ◽  
pp. 2323-2335
Author(s):  
Nicole Weeks ◽  
Fiona E.J. McDonald ◽  
Pandora Patterson ◽  
Stephanie Konings ◽  
Jane Coad
Keyword(s):  
Young Adult ◽  
Adult Children ◽  
Scoping Review ◽  
Information Resources ◽  
Adolescent And Young Adult ◽  
Online Information ◽  
High Quality

scholarly journals The Burden of Late Effects and Related Risk Factors in Adolescent and Young Adult Cancer Survivors: A Scoping Review

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4870
Author(s):  
Charlotte Ryder-Burbidge ◽  
Ruth L. Diaz ◽  
Ronald D. Barr ◽  
Sumit Gupta ◽  
Paul C. Nathan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Young Adult ◽  
Cancer Survivors ◽  
Scoping Review ◽  
Late Effects ◽  
Chronic Conditions ◽  
Adolescent And Young Adult ◽  
Cancer Type ◽  
Calendar Period ◽  
Late Mortality

Risk factors associated with late effects in survivors of adolescent and young adult (AYA) cancer are poorly understood. We conducted a systematic scoping review to identify cohort studies published in English from 2010–2020 that included: (1) cancer survivors who were AYAs (age 15–39 years) at diagnosis and (2) outcomes of subsequent malignant neoplasms (SMNs), chronic conditions, and/or late mortality (>5 years postdiagnosis). There were 652 abstracts identified and, ultimately, 106 unique studies were included, of which 23, 34, and 54 studies related to the risk of SMNs, chronic conditions, and mortality, respectively. Studies investigating late effects among survivors of any primary cancer reported that AYA cancer survivors were at higher risk of SMN, chronic conditions, and all-cause mortality compared to controls. There was an indication that the following factors increased risk: radiation exposure (n = 3) for SMNs; younger attained age (n = 4) and earlier calendar period of diagnosis (n = 3) for chronic conditions; and non-Hispanic Black or Hispanic (n = 5), low socioeconomic status (n = 3), and earlier calendar period of diagnosis (n = 4) for late mortality. More studies including the full AYA age spectrum, treatment data, and results stratified by age, sex, and cancer type are needed to advance knowledge about late effects in AYA cancer survivors.

Sign in / Sign up

Export Citation Format

Share Document